5 Key Takeaways

• 1

  EYP-1901 is a novel intravitreal insert that provides sustained release of vorolanib for at least six months after a single injection.

• 2

  In the DAVIO 2 trial, EYP-1901 demonstrated noninferiority to aflibercept in improving best-corrected visual acuity in wet AMD patients.

• 3

  EYP-1901 maintained stable vision and central subfield thickness for six months, outperforming the sawtooth pattern seen with aflibercept.

• 4

  The VERONA trial showed that EYP-1901 achieved extended time-to-first supplemental injection and significant vision improvements in DME.

• 5

  Ongoing phase 3 trials for EYP-1901 aim to further evaluate its efficacy in wet AMD and DME, with results expected by mid-2026.